Form 4 for SANA Sana Biotechnology, Inc.
Accepted 2025-03-10 00:00:00 ET · period of report 2025-03-06 · accession 0001562180-25-002271 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-10 | 2025-03-10 | SANA | Harr Steve | Pres, CEO, Dir | F - Tax | $2.56 | -12.8K | 7.88M | -0.2% | -$32.8K |
| D | 2025-03-10 | 2025-03-07 | SANA | Harr Steve | Pres, CEO, Dir | M - OptEx | $0.00 | +50.0K | 7.89M | +0.6% | $0 |
| DM | 2025-03-10 | 2025-03-06 | SANA | Harr Steve | Pres, CEO, Dir | A - Grant | $0.00 | +916.7K | 166.7K | New | $0 |
| D | 2025-03-10 | 2025-03-07 | SANA | Harr Steve | Pres, CEO, Dir | M - OptEx | $0.00 | -50.0K | 150.0K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-10 | F | D | 12,820 | $2.56 | 7,876,930 | D | — | — | |
| 2 | Common | Common Stock | 2025-03-07 | M | A | 50,000 | $0.00 | 7,889,750 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-03-06 | A | A | 750,000 | $0.00 | 750,000 | D | $2.55 · — to 2035-03-05 | 750,000 Common Stock | (F4) The option vests and becomes exercisable as to 25% of the underlying shares on March 6, 2026 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
| 4 | Derivative | Restricted Stock Units | 2025-03-06 | A | A | 166,667 | $0.00 | 166,667 | D | — · — to — | 166,667 Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. (F3) The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
| 5 | Derivative | Restricted Stock Units | 2025-03-07 | M | D | 50,000 | $0.00 | 150,000 | D | — · — to — | 50,000 Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. (F5) The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. |